Venetoclax and Selinexor in Treating Patients With Relapsed or Refractory High Risk Hematologic Malignancies
Conditions: Diffuse Large B-cell Lymphoma; Acute Myeloid Leukemia; Non-Hodgkin's Lymphoma Interventions: Drug: Venetoclax; Drug: Selinexor Sponsors: Michael Byrne; Karyopharm Therapeutics Inc; AbbVie Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials